FDA — authorised 1 September 2017
- Application: BLA761060
- Marketing authorisation holder: WYETH PHARMS INC
- Indication: Efficacy
- Status: approved
FDA authorised OZOGAMICIN on 1 September 2017
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 1 September 2017; FDA authorised it on 6 March 2024.
WYETH PHARMS INC holds the US marketing authorisation.